code: 4188



AmCad BioMed Corporation

2023 Institutional Investor Conference

Chairman and CEO Yili Lee 2023/11/28





- 1.Apart from historical data, the matters listed in this presentation that are forward-looking statements may be subject to significant risks and uncertainties, which could result in differences between these forward-looking statements and actual outcomes.
- 2.The future projections presented in this document reflect the company's views as of the current date. However, the company is not obligated to update this information in case of any events or changes in the environment.
- 3. Without the company's permission, the copying, modification, recompilation, reduction, or transmission of any content in this presentation, or the use of any such content for commercial purposes, is strictly prohibited.
- 4. The content of this presentation includes all entities belonging to the consolidated financial statements.

Company Profile



字古生医 Pioneering Ultrasound Al

Helping physicians diagnose confidently and efficiently

The first medical device company to obtain FDA approval for ultrasound computer-aided diagnosis (CAD) in the United States. Leveraging world-leading technology combined with artificial intelligence (AI) and medical expertise, we are committed to addressing unmet clinical needs, providing optimal solutions, and serving as a pioneer in intelligent medical imaging.

Founded

Dec. 2008

Business

Product development, Manufacturing and Sales for Innovative Medical Device

Capital

TWD 530M

Subsidiary

Broadsound Corporation

President

Yili Lee

Number of Employees

75

*CAD = Computer-Aided Detection







Regulatory Certification









Obtained MDR CE certificate in November 2023.

AmCad BioMed Corporation

5F., No. 167, Fuxing N. Rd., Songshan Dist., Taipei City 105403, Taiwan (R.O.C.) SRN: TW-MF-000013445

has been assessed and certified as meeting the requirements of


MDR EU Quality Management System certificate (Annex IX QMS)

For the following products
Class III - MDA0315 MDS1

Class IIa - MDA0315, MDS100


Milestones





Milestones






In 2023, AmCAD UT [®] start business in three internationally renowned institutions:Kochi University in Japan, the Advanced AI Clinic in Dubai, UAE, and a well-known thyroid specialist hospital in Berlin, Germany. Demonstrating AmCAD UT [®] recognition in the global market.

AmCAD-UO [®] commenced sales in 2022 and has been implemented in medical facilities in Taiwan and Thailand.

Product Lines






*AmCAD UT® Features







- FDA 510(k), CE, TFDA, CFDA certified
- Automated nodule identification and segmentation
- Patented technologies to visualize and quantify sonographic features
- Recommendation based on TI-RADS and global guidelines
- Automated report generation



Visualization of Thyroid Ultrasound Features



Automated report generation

AmCAD UO[®] Features








Detection system for Obstructive Sleep Apnea


- FDA 510(k), CE, TFDA certified
- Patented Laser Guided Positioning
- Algorithmic Detection and Analysis
- Automated Upper Airway Scanning on Awake Patients
- Rapid testing with automated report generation.





Roadmap of Medical Innovation Development





Continued Execution

- ▶ Product KFDA Certification Application.
- ► Applying for the European Health Insurance Claim Code.
- ► Continue to promote domestic hospitals and health diagnosis channels.(NTUH Health Management Center)
- Execute post-market clinical research and paper publication with well-known teaching hospitals at home and abroad, and expand product application.
- To accumulate product popularity by exhibiting, Internet publicity.

Completed this year

- ► CE MDR certificate.
- Conducted post-market clinical research in collaboration with Stanford Medical Center and NTUH Health Management Center, and published the enrollment results after the market launch.
- UT+UO has published 35 research papers.

Key Marketing Events of 2023



Domestic

- AmCAD UT® start business in Kaohsiung Medical University Chung-Ho Memorial Hospital, Taipei Medical University Shuang-Ho Hospital, Tri-Service General Hospital Penghu Branch, Min-Sheng General Hospital, and St. Martin de Porres Hospital.
- AmCAD UO® start business in NTUH Health Management Center • China Medical University Hospital • Harvard Clinic.
- Held Applications of Upper Airway Ultrasound Al inSleep Science Forum on May 27th.
- Participated in BioAsia for marketing promotion.
- Collaborated with NTUH Health Management Center to publish the results of the enrollment study.
- Collaborated with My lux vitae for corporate screening, coupled with the sale of OSA auxiliary therapy devices.

International

- Participated in exhibitions for marketing promotion: Arab Health in January, Thailand ENT Congress in May, Medical Fair Asia in August, Taiwan Thailand Smart Healthcare Conference, and Medica in November, enhancing product visibility.
- Collaborated with Stanford Sleep Center to publish a paper in JAMA Oto in May and delivered three presentations at the World Sleep Congress in October.
- Collaborated with National Taiwan University Dental Department to present midterm enrollment results at the APSS in June.
- Swiss clinical case applying for European insurance code.
- Initiated clinical research collaboration with two major hospitals in Thailand.

* AmCAD UO® testing implementation







China Medical University Hospital-Taichung Branch





 Held Applications of Upper Airway Ultrasound AI inSleep Science Forum with Taiwan Society of Sleep Medicine.













•	08:30 - 09:00 Reception								
09:00 09:10	Opening	Speaker :	臺	北	榮	民態	! 醫	院	/周昆達醫師
09:10 09:40	Seeing the sound of sleep	Speaker : Moderator :			rd U		sity 翳	1.411	ool of Medicine Dr. Stanley Liu /李學禹醫師
09:40 09:50	Discussion	Panelist :	長成	庚	紀大	念醫	翳	院	/林婉妮 醫師 /林政佑 醫師

	09:50 - 10:	00 Break Time
10:00 1 10:30	Observing the Changes of Tongue and Airway Configurations in Responders of Mandibular Advancement Device Using Standardized 3D Ultrasound Imaging	Speaker : 國立台灣大學醫學院附設醫院 / 陳韻之醫師 Moderator: 高雄醫學大學附設中和紀念醫院 / 陳裕豐醫師
10:30 1 10:40	Discussion	Panelist : 衛生福利部雙和驚院/劉文德馨師 臺北市立萬芳醫院/洪士涵醫師
10:40 1 11:10	Upper Airway Ultrasound in the application of OSA screening in the Health Checkup Cohort	Speaker : 國立台灣大學醫學院附設醫院 / 謝敦理 無統 Moderator: 國立台灣大學醫學院附設醫院 / 李佩玲 無統
11:10 1 11:20	Discussion	Panelist:中國醫藥大學附設醫院/杭良文醫師台北馬偕紀念醫院/劉景隆醫師
11:20 11:30	Closing	Speaker : 長 庚 紀 念 醫 院 /陳濘宏器師

Our exhibition received recognition from the mayor of Taipei.











AmCAD UO® National Taiwan University Hospital press conference.



May 2020



Project initiation


The application of upper airway 3D ultrasound imaging in the clinical assessment of OSA.

Target number

>1000 people

September 2023

Preliminary results presentation:
Severe patients screened out through
AmCad UO are arranged to go to the
sleep center for further examination.
Accuracy rate as high as 95%





NTUH Health Management Center officially adopts AmCAD UO® sleep to rapid screen.



People undergo non-invasive examinations while lying in an awake state. Using laser guidance for positioning and an automated probe for scanning, coupled with analysis by artificial intelligence software, the severity of sleep apnea can be determined within 10 minutes without the need for an overnight stay.







Media coverage



<u>=</u>Q

工商時報

安克10分鐘睡眠檢測台 大醫院採用

有助提升病友睡眠與生活品質,降低日 後罹病的醫療支出與生產力減損,守護 更多國人健康

2023.09.21 / 03:00 / 工商時報 李水蓮



●安克生醫免過夜、10分鐘完成的超音波智慧睡眠 檢測系統,獲台大醫院健康管理中心正式引用。圖 / 業者提供

三立新聞網 > 生活

台大首創超音波「睡眠快篩」 不用「睡一晚」10分鐘抓出9成 呼吸中止症

2023/09/04 13:47

記者黃仲丘/台北報導

台大推「睡眠快篩」! 15分 鐘就能揪出呼吸中止症

14:24 2023/09/04 中時 林周義



台大醫院與安克生醫合作開發「人工智慧超音波睡眠 監測儀」,幫助民眾做睡眠「快篩」。(台大醫院提 供 / 林周義台北傳真)

健康20

10~15分鐘快篩睡眠呼吸中止症!超 音波結合AI準確率達9成 青壯年高風 險竟占半數

許寶仁 報導 | ② 2023/09/04 18:25

自由健康網

Q =



健康 - 杏林動態

睡眠呼吸中止症 也能快篩

2023/09/05 05:30









AmCAD UO® online promotion





10.11.23【直播 愛健康 @icarebcc】「快篩」 可揪出...

主持人:李雅媛 現場來賓:肝病防治基金會執行長 粘曉菁醫師中廣...



Participation in the Medical Fair Thailand.




Participation in the Medical Fair Thailand, an Asian medical exhibition.

Gathering with Thai agents and local Key Opinion Leader (KOL) doctors.











Participation in Taiwan Thailand Smart Healthcare Conference.



Collaborates with agents to showcase on-site ultrasound AI medical technology, contributing to the penetration of smart healthcare into the Thai market.



經濟日報 > 商情 > 熱門亮點

台泰智慧醫療研討會盛況空前!彰基助台 業者開拓泰國市場

本文共696字











經濟日報鄭芝珊 6 3 10


由台灣彰化基督教醫院 (簡彰基) 舉辦、當地媒體夥伴Vision Thai 看見 泰國所執行的「台泰智慧醫療研討會」於日前在曼谷圓滿落幕。作為台灣 每年東南亞最大規模的智慧醫療交流盛會,今年彰基帶領20家台灣智慧醫 療廠商參與,以AI結合醫療科技應用於精準與再生醫療為主軸,吸引250 位泰國醫衛相關人士出席,除了為台灣廠商開拓市場,更將台灣的智慧醫 療技術應用推向國際。



臺泰智慧醫療研討會曼谷登場,吸引250名泰國醫衛人士出席。看見泰國/提供

National Taiwan University Dentistry Mid-year presentation in APSS







Stanford Medical Center has published research findings in world-class journals.



July 2020



Project initiation

March 2022



Mid-year presentation: In comparison with DISE and PSG testing, it shows a high degree of consistency.

May 2023

JAMA Otolaryngology-Head & Neck Surgery

Paper results published: Predicting the risk of moderate to severe OSA with an accuracy of up to 90%


October 2023



The results of three speeches were published: Provide physicians with evaluation for subsequent treatment of OSA, including evaluation of the suitability of anti-snoring braces and CPAP.

JAMA Otolaryngology-Head & Neck Surgery

Editor's Choice: The Latest in Otolaryngology in JAMA



Backscattered Ultrasonographic Imaging of the Tongue and Severity of Obstructive Sleep Apnea

Stanley Y. C. Liu, MD, DDS; Pien F. N. Bosschieter, MD, PhD; Mohammed Abdelwahab, MD, PhD; et al Original Investigation | May 11, 2023

ONLINE FIRST

Just Published May 11, 2023

Participation in the World Sleep Congress.









Keynote Session

Date: Monday, 23rd October 2023

Time: 14:00 - 14:45

Location: Room 24 | Oceania 10

Title: Sleep Surgery as Restoring Missed Milestones in Airway Growth

and Development Speaker: Stanley Liu, US

Symposium

Date: Tuesday, 24th October 2023

Time: 15:00 - 16:30 Location: Room 7

Title: Seeing the Sound of Sleep

Chairs: Clete Kushida, US & Stanley Liu, US

Oral Abstract Session

Date: Wednesday, 25th October 2023

Time: 15:00 - 16:30

Location: Room A06 | Oceania 08

Title: Sleep Disordered Breathing: Modeling, Predictors, and

Pathogenetic Mechanisms

Chairs: Diane Lim, US & Bingqian Zhu, CN





2023Q4 ` 2024 plans for business & marketing activities.



Domestic

Healthcare 2023.11.30-12.03 EXPO · TAIWAN 台灣醫療科技展

Established AmCad line@



International



INTERNATIONAL SURGICAL SLEEP SOCIETY

ISSS 2024 ANNUAL MEETING

January 24-26, 2024

Wollongong, Australia



Business Model





Use our expertise in developing product according to our strategic partners' needs/specifications.



Distribution

Leasing

Revenue Sharing Outright Sales

Subscription

Exclusive or regional rights, single & multi-product deals.



Collaborative Marketing

Collaborate with enterprise imaging solutions providers to expand market access.

Future development strategy

UB "technical cooperation and licensing opportunities.



Technology collaboration, licensing, or cooperative development
Complementary technology with major international ultrasound
manufacturers: Combining our AI ultrasound technology with the products
of major international ultrasound manufacturers, we can develop "AmCAD

☐ 「AmCAD UO」 Market expansion

Cooperate with major manufacturers of CPAP to improve screening efficiency, and establish cooperation with major manufacturers in APAC to expand the Asia-Pacific market based on the existing customer in the market.

■ Market sharing

Mutual technology licensing between both parties in the imaging platform industry, operating in the market, sharing customers and profit.

☐ Actively signing agreements with distributors in multiple countries.



GE HealthCare snaps up ultrasound AI maker Caption Health.





Caption Health's Al software walks healthcare workers through the process of securing clear images from cardiac ultrasound exams—even if they've never performed or received training for the finicky and very precise procedure. (Caption Health)

Once under the GE HealthCare umbrella, Caption's AI will be embedded into the medtecl giant's ultrasound devices. According to Karley Yoder, chief digital officer of GE HealthCare's ultrasound business, the technology will first be added to its point-of-care and hand-held imaging devices.

Meanwhile, Caption will continue to build up its network of technicians who have been trained to use the AI to provide cardiac ultrasounds in care settings beyond traditional hospitals and, eventually, in patients' homes.

"Guiding ultrasound users during examinations with the help of AI is of growing importance, especially as we reach a broader set of healthcare professionals. Caption Health's AI applications help enable reliable, consistent ultrasound examinations to deliver more precise diagnoses, improved treatment decision-making and ultimately improved patient outcomes," said Roland Rott, president and CEO of GE HealthCare's ultrasound segment. "This tuck-in acquisition will help expand affordable access to ultrasound imaging to novice users and is aligned with a broader shift to precision care globally."



Financial Information

Consolidated Balance Sheet



ITEMS	2023.09.30	%	2022.12.31	%
Current Assets	330,141	63	359,881	65
Non-current Assets	189,445	37	193,981	35
Total Assets	519,586	100	553,862	100
Current Liabilities	22,870	5	27,360	5
Non-current Liabilities	11,383	2	6,720	1
Total Liabilities	34,253	7	34,080	6
Capital	532,791	103	532,214	96
Additional Paid-in Capital	7,541	1	95,738	17
Accumulated Deficit	(137,841)	(27)	(192,055)	(34)
Other Equity	(10,779)	(2)	(11,315)	(2)
Parent Equity	391,712	75	424,582	77
Minority Interest	93,621	18	95,200	17
Total Equity	485,333	93	519,782	94
Total Liabilities and Equity	519,586	100	553,862	100

[▶] Debt ratio : 6.6% · Cash sufficient · and the financial structure is healthy.

Consolidated Income Statement



Unit: KTWD

ltems	2023Q3		2022 Ç	YoY	
	AMT	%	AMT	%	%
Sales Revenue	41,842	100	47,837	100	(13)
Gross Margin	25,188	60	29,101	61	(13)
Operating Expenses	(68,640)	(164)	(70,984)	(148)	(3)
Operating Loss	(43,452)	(104)	(41,883)	(87)	-
Non-operating Gain	7,461	18	7,888	16	(5)
Net Loss	(35,991)	(86)	(33,995)	(71)	-
Net Loss – Parent	(34,412)	(82)	(33,323)	(70)	-
Net Loss – Minority	(1,579)	(4)	(672)	(1)	-
EPS (TWD)	(0.65)		(0.63)		

► The operating income decreased compared to the same period last year, primarily due to lower-than-expected revenue in China. However, AmCAD UO® revenue for this year has shown significant growth compared to the previous year, and with effective cost control. Therefore, the two periods loss is approximately equivalent.



Future Development

AmCAD UO® Product Applications



1. Replace Polysomnography (PSG)

Home Sleep Test (HST)


Utilizing AmCAD UO® 10-minute rapid test, it achieves a 95% accuracy in OSA diagnosis, offering a more convenient and comfortable alternative for patients.

2. OSA Treatment Guidelines

Identifying VOTE obstruction and tongue muscle conditions, doctors can provide individualized recommendations for various treatment options, such as positive airway pressure devices, orthodontic braces, surgical excision, laser ablation, and neural stimulation.

3. Tracking before and after treatment

Utilize AmCAD UO® for continuous monitoring to track the effectiveness of OSA treatment.



















THANK YOU!



Official account



Groups